Extra MRI did not improve Long COVID fatigue in a large care-pathway trial
Fatigue improved across all groups receiving specialist care, but adding multi-organ MRI produced no measurable advantage at 12 weeks.
Clinical trials, diagnosis, public health, nutrition, aging and treatment—with extra scrutiny for claims that could affect care.
These hubs combine the newest records with method guidance and live counts from the database.
Trials and evidence on heart failure, atrial fibrillation, prevention, procedures and the practical problem of getting effective care into everyday use.
Open research hub →Health & MedicineDrug trials, nutrition, diabetes and metabolic health, with weight change separated from long-term health outcomes and individualized medical advice.
Open research hub →Fatigue improved across all groups receiving specialist care, but adding multi-organ MRI produced no measurable advantage at 12 weeks.
The drug produced double-digit average weight loss, while gastrointestinal side effects were frequent and discontinuation matters.
Rhythm-control success was higher at one year, but the device procedure still carried risks and industry funding deserves attention.
The device was noninferior for cardiovascular death, stroke or embolism and reduced non-procedural bleeding over three years.
Patients of trained physicians reached HbA1c targets more often, but the intervention tested implementation—not a new diabetes treatment.
The system improved oxygen-range control compared with usual care; clinical outcomes and safe implementation still need evaluation.
Intravenous anesthesia did not improve the primary recovery outcome, though some next-day discomforts were less frequent.
LTG-001 targets peripheral pain signaling without being an opioid, but comparative effectiveness and broader safety remain unsettled.
Balance, agility, lower-body strength and cardiorespiratory fitness were associated with survival, but the observational design cannot prove that testing or training caused it.
A federal risk assessment combined outbreak reports, travel patterns and response capacity to judge the near-term likelihood of U.S. importation and spread.
CDC researchers compared plausible transmission and intervention scenarios to estimate how timing and control strength could affect an Ebola outbreak.
NIH-highlighted research tested a way to quiet immune cells involved in organ rejection while trying to preserve broader immune function.
NIST testing found that use-related wear can alter how fluorinated chemicals are measured in protective gear, complicating exposure and replacement decisions.
A Cornell-led study connected stress, bacteriophages in the gut and weaker antitumor immunity in experimental systems.
The result is promising for diagnosis—but it was not a general-population screening test, and accuracy is not the same as improved patient outcomes.